Neurotech International (NTI) AI Stock Analysis

• Market Cap: AU$18.15M
• Dividend Yield: N/A
• Average Volume (3M): 768.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: -87.88%
• EPS Growth: -83.93%
• Country: AU
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 1,296,313,100
• 10 Day Avg. Volume: 770,041
• 30 Day Avg. Volume: 768,844
• PEG Ratio: -0.02
• Price to Book (P/B): 5.26
• Price to Sales (P/S): 6.36
• P/FCF Ratio: -1.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.01
• Revenue Forecast (FY): AU$6.58M

• Rating: 45 Neutral
• Price Target: AU$0.01 ▼(-35.00% Downside)

The score is primarily constrained by weak financial performance—persistent heavy losses, worsening free cash flow burn, and a shrinking equity base—despite a notable FY2025 revenue rebound and no debt. Technicals are also unfavorable with a clear below-average trend and negative MACD, while valuation is difficult to support due to negative earnings and no dividend.

Positive Factors

Focused therapeutic R&D

Specialized R&D focus on neurological and neurodevelopmental therapies, including cannabinoid-based compounds, builds domain expertise and potential differentiated IP. This niche orientation supports durable partnership, licensing and clinical-development advantages over the medium term.

Low financial leverage

A zero-debt balance sheet materially reduces solvency and interest-rate risk, giving management structural flexibility to prioritize R&D or negotiate non-dilutive partnerships. Over 2–6 months, low leverage improves survival odds while cash burn is managed or refinanced.

FY2025 revenue rebound with high gross margin

A sharp FY2025 revenue rebound from a near-zero base, combined with a reported 100% gross margin, indicates early commercial traction or high-margin licensing/royalty dynamics. If sustained, this supports scalable revenue growth and a clearer path to narrowing operating losses.

Negative Factors

Accelerating cash burn

Consistent negative operating and free cash flow with an accelerating FY2025 FCF deficit (~-A$9.0m) creates an ongoing funding requirement. Structurally, this forces reliance on capital markets or partners, increasing dilution risk and constraining long-term R&D and commercialization plans.

Persistent deep operating losses

The company reports very large negative EBIT and net margins (operating costs far exceed revenue; cited ~-4.4x revenue), indicating structural unprofitability at current scale. Sustained operating deficits limit ability to self-fund growth and heighten execution risk until revenue scales markedly.

Shrinking equity base and capital volatility

Material decline in equity to A$3.0m from A$11.9m reflects accumulated losses and capital movements, reducing the balance-sheet buffer. Over the medium term this raises vulnerability to funding shortfalls and makes future raises more dilutive, constraining strategic optionality.

Neurotech International Business Overview & Revenue Model

Company Description

Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercializing Mente platform, a platform technology to monitor and play role in home-based therapies. Its product includes Mente Autism for the diagnosis and treatment of autism. It also engages in executing of medical research projects; and developing of technological devices. The company was incorporated in 2016 and is based in Nedlands, Australia.

How the Company Makes Money

Neurotech International Ltd. generates revenue primarily through the sale of its medical devices and related solutions. The company's key revenue streams include direct sales to healthcare providers, licensing agreements, and partnerships with medical institutions. NTI also invests in research and development to enhance its product offerings, which can lead to increased adoption and market penetration. Significant partnerships with healthcare organizations and collaborations in clinical trials further contribute to its revenue by expanding its reach and validating its products' efficacy in treating neurological conditions.

Neurotech International Financial Statement Overview

Summary

Neurotech International Ltd. is experiencing significant financial challenges, characterized by declining revenues and consistent losses across its income statement. Despite a solid balance sheet with no debt and a strong equity base, the company's negative cash flows and reliance on external financing pose risks to financial stability.

Income Statement

The company has consistently reported negative net income and declining revenues over the years. The gross profit margin is negative, indicating that the cost of goods sold exceeds total revenue. There is also a significant decline in EBIT and EBITDA margins, highlighting operational inefficiencies. The revenue growth rate is negative, reflecting a downward trend in sales.

Balance Sheet

The company has a strong equity position with no debt, as indicated by the debt-to-equity ratio of zero. The equity ratio is high, showing a solid financial structure. However, the company is facing consistent losses, which could impact future equity levels. The return on equity is negative due to recurring net losses.

Cash Flow

Operating cash flows are negative, indicating challenges in generating cash from core business activities. The free cash flow is also negative, suggesting limited room for reinvestment or debt repayment. The company is reliant on financing activities to support cash flow needs. There is a lack of positive free cash flow growth, which highlights cash management issues.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.44M	2.44M	1.96K	5.96K	38.26K	206.14K
Gross Profit	2.44M	2.44M	-5.87K	4.21K	-535.21K	-238.72K
EBITDA	-10.74M	-10.74M	-8.24M	-8.98M	-3.36M	-7.43M
Net Income	-10.60M	-10.60M	-5.07M	-7.79M	-3.36M	-7.43M
Balance Sheet
Total Assets	3.24M	3.24M	12.21M	5.31M	2.02M	5.01M
Cash, Cash Equivalents and Short-Term Investments	3.03M	3.03M	11.63M	5.03M	1.90M	4.83M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	285.74K	285.74K	314.70K	1.35M	592.98K	1.14M
Stockholders Equity	2.95M	2.95M	11.90M	3.96M	1.43M	3.86M
Cash Flow
Free Cash Flow	-9.02M	-9.02M	-4.60M	-6.32M	-2.96M	-2.32M
Operating Cash Flow	-9.02M	-9.02M	-4.60M	-6.32M	-2.96M	-2.32M
Investing Cash Flow	0.00	0.00	0.00	0.00	-3.21K	0.00
Financing Cash Flow	429.53K	429.53K	11.19M	9.45M	26.40K	7.13M

Neurotech International Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NTI, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.57 is Neutral, neither overbought nor oversold. The STOCH value of -150.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NTI.

Neurotech International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CBL	51 Neutral	AU$24.31M	-2.53	-103.74%	―	14.84%	39.64%
AT1	48 Neutral	AU$28.36M	-4.68	-58.27%	―	-7.20%	28.70%
NTI	45 Neutral	AU$18.15M	-1.26	-142.71%	―	-87.88%	-83.93%
IRX	43 Neutral	AU$5.66M	-3.71	―	―	―	-55.00%
OSL	39 Underperform	AU$16.44M	-0.62	-385.20%	―	126.62%	33.53%
ADR	37 Underperform	AU$21.46M	-0.64	-1476.79%	―	-2.82%	32.47%

Neurotech International Corporate Events

Neurotech Issues New Shares, Affirms Regulatory Compliance

Neurotech International has issued new ordinary fully paid shares without a prospectus under the Corporations Act, confirming that it remains compliant with its financial reporting and continuous disclosure obligations and that there is no excluded information that would reasonably be expected in a formal disclosure document. The board-authorised move signals routine capital management by the clinical-stage paediatric neurology specialist, with the company emphasising regulatory compliance as it advances development of its NTI164 cannabinoid therapy across multiple neurological indications.

Neurotech Seeks ASX Quotation for 246.7 Million New Shares

Neurotech International has applied to the ASX for quotation of 246.7 million new ordinary fully paid shares, expanding its listed securities on the Australian market. The issuance, lodged via an Appendix 2A application and tied to previously flagged transactions, significantly increases the company’s share count and is likely to affect its capital structure and liquidity profile for existing and prospective shareholders.

Neurotech Director’s 5 Million Options Lapse, Reducing Potential Equity Exposure

Neurotech International has disclosed a change in director Gerald Quigley’s interests, confirming the lapse of 5,000,000 unlisted options (NTIOPT20, exercisable at $0.10 and expiring 23 December 2025), which were held directly. Following this lapse, Quigley’s remaining interest is an indirect holding of 277,777 fully paid ordinary shares via a nominee and custodial structure, with no cash consideration involved and no trades occurring during a closed period, indicating a reduction in his potential equity exposure while leaving his existing shareholding intact.

Neurotech Options Lapse, Streamlining Capital Structure

Neurotech International Limited has allowed 5 million unlisted options, exercisable at $0.10 and due to expire on 23 December 2025, to lapse without being exercised. The expiry of these options reduces the company’s pool of potential future equity issuance, slightly simplifying its capital structure but having no immediate impact on the number of ordinary shares on issue or existing shareholders’ current holdings.

Neurotech International Secures $4 Million to Advance Paediatric Neurological Treatments

Neurotech International has secured binding commitments for a $4 million placement from both existing and new investors, with directors also participating. The funds will be used to advance NTI164’s non-clinical toxicology and clinical programs, regulatory submissions, and general working capital, strengthening the company’s position in developing treatments for paediatric neurological disorders.

Neurotech International Initiates Trading Halt for Capital Raising Announcement

Neurotech International Limited has requested a trading halt on its securities pending an announcement related to a capital raising initiative. This move indicates a strategic step by the company to potentially enhance its financial resources, which could impact its market positioning and stakeholder interests.

Neurotech International’s AGM Reflects Strong Shareholder Support

Neurotech International Limited held its Annual General Meeting, where all resolutions were determined by a poll. The meeting’s outcomes, including the adoption of the remuneration report and re-election of Mark Davies, were carried successfully, indicating strong shareholder support. This meeting underscores Neurotech’s stable governance and continued focus on advancing its clinical programs, potentially enhancing its position in the biopharmaceutical industry.

Neurotech Secures $4.73 Million R&D Tax Incentive for Clinical Advancements

Neurotech International Limited has received a $4.73 million R&D tax incentive refund from the Australian Government for the financial year ending June 2025. The company plans to use these funds to further develop its clinical pipeline for paediatric neurological disorders and support its working capital, potentially enhancing its operational capabilities and market position in the biopharmaceutical industry.

Neurotech Expands NTI164 Access and Gains FDA Designation

Neurotech International has initiated an Authorised Prescriber program for its lead therapy, NTI164, in Australia, aimed at expanding access and collecting real-world data to support regulatory submissions and market positioning. Additionally, the company received a Rare Pediatric Disease Designation from the US FDA for NTI164 in treating Rett Syndrome, enhancing its strategic position and regulatory support, while progressing with long-term safety studies and planning further clinical trials.

Neurotech International Announces 2025 Annual General Meeting

Neurotech International Ltd has announced its Annual General Meeting (AGM) scheduled for 20 November 2025 in Melbourne. The meeting will be held physically, but shareholders can participate by voting online or submitting proxy forms. This decision underscores the company’s commitment to shareholder engagement and transparency, allowing stakeholders to stay informed and involved in the company’s governance.

Neurotech International Releases 2025 Annual Report

Neurotech International has released its 2025 Annual Report, detailing key corporate activities and financial statements. The report highlights the company’s operational review, corporate activities, and audited remuneration report, providing stakeholders with insights into its financial health and strategic direction.